Cancer Research and Treatment10.4143/crt.2018.2622019512727-736Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry DataEun Kyoung Kim, Jinhyun Cho, Ji-Yeon Kim, Sung-A Chang, Sung-Ji Park, Jin Oh Choi, Sang Chol Lee, Jin Seok Ahn, Seung Woo Park, Young-Hyuck Im, Eun Seok Jeon, Yeon Hee Park,,
British Journal of Cancer10.1038/sj.bjc.6600346200286111697-1700Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patientsT Nousiainen, E Jantunen, E Vanninen, J Hartikainen,,
Reactions Weekly10.1007/s40278-017-38797-420171679172-72Epirubicin/trastuzumab,,
Reactions Weekly10.1007/s40278-016-19415-2201616091119-119Trastuzumab,,
Reactions Weekly10.1007/s40278-014-5210-y201415281203-203Trastuzumab,,
Reactions Weekly10.1007/s40278-015-4134-5201515631205-205Trastuzumab,,
Value in Health10.1016/j.jval.2014.08.1302014177A739Change in Percentage of Left Ventricular Ejection Fraction in Breast Cancer Patients Received Trastuzumab TreatmentN Areepium,
Annals of Oncology10.1093/annonc/mdy300.030201829suppl_81713PLeft ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillanceJ H Yeo, H Ahn, I Park, Y S Kim, S J Sym, E K Cho, D B Shin
Echocardiography10.1111/echo.131682016334519-526Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection FractionHong-wen Fei, Mohammed T. Ali, Timothy C. Tan, Kai-Hung Cheng, Laura Salama, Lanqi Hua, Xin Zeng, Elkan F. Halpern, Alphonse Taghian, Shannon M. MacDonald, Marielle Scherrer-Crosbie
Reactions Weekly10.1007/s40278-019-62580-520191755126-26Anthracyclines/trastuzumab,,